

Supplementary Table 1: Univariate analysis of factors associated with ustekinumab discontinuation

Variable	UST Discontinued	UST Continued	p-value
Number of patients	17	93	
Age at ustekinumab initiation, years (IQR)	38 (29-46)	41 (29-61)	0.211
Male sex, n (%)	11(65)	54 (58)	0.790
Disease duration, years (IQR)	7 (3-11)	7 (3-14)	0.817
Extensive colitis, n (%)	6 (35)	53 (57)	0.118
Current smoker, n (%)	3 (18)	2 (2)	<b>0.026</b>
Baseline corticosteroid use, n (%)	11(65)	54 (58)	0.790
Baseline immunomodulator use, n (%)	2 (12)	11 (12)	>0.999
Previous anti-TNF, n (%)	14 (82)	57 (61)	0.108
Previous vedolizumab, n (%)	14 (82)	45 (48)	<b>0.016</b>
Previous anti-TNF + vedolizumab, n (%)	12 (71)	24 (26)	<b>0.001</b>
Previous tofacitinib, n (%)	11(65)	24 (26)	<b>0.003</b>
Previous anti-TNF + vedolizumab + tofacitinib	9 (53)	10 (11)	<b>0.0002</b>
Baseline CRP, mg/L (IQR)	3 (2-9)	4 (1-9)	0.974
Baseline faecal calprotectin, µg/g (IQR)	447 (333-1500)	611 (265-919)	0.909
Baseline weight, kg (IQR)	74 (43-90)	75 (66-87)	0.665

Supplementary Table 2: Multivariate analysis of factors associated with ustekinumab discontinuation

Variable	Odds Ratio	p-value
Current smoker	0.03 (0.0024-0.36)	0.006

Supplementary Table 3: Univariate analysis of factors associated with clinical remission between weeks 14-16 following ustekinumab induction

Variable	Non-Remission	Remission	p-value
Number of patients	25	23	
Age at ustekinumab initiation, years (IQR)	38 (29-44)	51 (29-61)	<b>0.027</b>
Male sex, n (%)	16 (64)	11 (48)	0.383
Disease duration, years (IQR)	5 (3-8)	8 (2-14)	0.190
Extensive colitis, n (%)	12 (48)	12 (52)	>0.999
Current smoker, n (%)	1 (4)	1 (4)	>0.999
Baseline corticosteroid use, n (%)	15 (60)	10 (43)	0.386
Baseline immunomodulator use, n (%)	2 (8)	3 (13)	0.660
Previous anti-TNF, n (%)	19 (76)	12 (52)	0.131
Previous vedolizumab, n (%)	19 (76)	8 (35)	<b>0.008</b>
Previous anti-TNF + vedolizumab, n (%)	15 (60)	5 (22)	<b>0.010</b>
Previous tofacitinib, n (%)	9 (36)	9 (39)	>0.999
Previous anti-TNF + vedolizumab + tofacitinib	7 (28)	5 (22)	0.743
Baseline CRP, mg/L (IQR)	3 (1-7)	3 (1-9)	0.554
Baseline faecal calprotectin, µg/g (IQR)	447 (258-800)	474 (135-1025)	0.992
Baseline weight, kg (IQR)	72 (66-90)	73 (59-82)	0.368